Iressa gefitinib: Phase II data; under FDA review for non-small cell lung cancer (NSCLC)

In an open-label Phase II trial of 22 breast cancer patients resistant to or not eligible for tamoxifen, 500 mg of once-daily Iressa gave 2 partial responses after 4 weeks. Ten patients had not progre...